These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 8490694)
41. Cephalosporin therapeutics for intensive care infections. Salacata A; Chow JW New Horiz; 1993 May; 1(2):181-6. PubMed ID: 7922401 [TBL] [Abstract][Full Text] [Related]
42. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827 [TBL] [Abstract][Full Text] [Related]
43. Monoclonal antibodies to endotoxin in the management of sepsis. Fang KC West J Med; 1993 Apr; 158(4):393-9. PubMed ID: 8317126 [TBL] [Abstract][Full Text] [Related]
44. Integrating rapid diagnostics and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant Gram-negative bacteremia. Perez KK; Olsen RJ; Musick WL; Cernoch PL; Davis JR; Peterson LE; Musser JM J Infect; 2014 Sep; 69(3):216-25. PubMed ID: 24841135 [TBL] [Abstract][Full Text] [Related]
45. Therapies directed against endotoxin--has the time come? Quezado ZM; Hoffman WD West J Med; 1993 Apr; 158(4):424-5. PubMed ID: 8317138 [No Abstract] [Full Text] [Related]
46. Clinical trials of immunotherapy for sepsis. Cunnion RE Crit Care Med; 1992 Jun; 20(6):721-3. PubMed ID: 1597020 [No Abstract] [Full Text] [Related]
47. Morbidity and mortality of bloodstream infections in patients with severe burn injury. Brusselaers N; Monstrey S; Snoeij T; Vandijck D; Lizy C; Hoste E; Lauwaert S; Colpaert K; Vandekerckhove L; Vogelaers D; Blot S Am J Crit Care; 2010 Nov; 19(6):e81-7. PubMed ID: 21041189 [TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients. Chalfin DB; Holbein ME; Fein AM; Carlon GC JAMA; 1993 Jan; 269(2):249-54. PubMed ID: 8417245 [TBL] [Abstract][Full Text] [Related]
49. The impact of an antibiotic cycling program on empirical therapy for gram-negative infections. Merz LR; Warren DK; Kollef MH; Fridkin SK; Fraser VJ Chest; 2006 Dec; 130(6):1672-8. PubMed ID: 17166981 [TBL] [Abstract][Full Text] [Related]
50. [Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients]. Costongs LG; Speelman P; van Lieshout JJ; van Deventer SJ; Lubbers MJ; Schipper HG Ned Tijdschr Geneeskd; 1993 Feb; 137(7):355-60. PubMed ID: 8437634 [TBL] [Abstract][Full Text] [Related]
51. Monoclonal antibodies and the treatment of gram-negative bacteremia and shock. Wolff SM N Engl J Med; 1991 Feb; 324(7):486-8. PubMed ID: 1988835 [No Abstract] [Full Text] [Related]
52. The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin. Arch Intern Med; 1994 Nov; 154(21):2484-91. PubMed ID: 7979845 [TBL] [Abstract][Full Text] [Related]